1. Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
   Esther M. van Wezel et al, 2019, JCO Precision Oncology CrossRef
2. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients
   Yania Yáñez et al, 2016, Journal of Cancer Research and Clinical Oncology CrossRef
3. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
   Fjoralba Zeka et al, 2018, JCI Insight CrossRef
4. Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma
   Yan Su et al, 2020, BMC Cancer CrossRef
5. Advances in liquid biopsy in neuroblastoma
   Zhenjian Zhuo et al, 2022, Fundamental Research CrossRef
6. Bottom up proteomics reveals novel differentiation proteins in neuroblastoma cells treated with 13-cis retinoic acid
   Effie G. Halakos et al, 2019, Journal of Proteomics CrossRef
7. The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review
   Ruben Van Paemel et al, 2020, European Journal of Pediatrics CrossRef
8. Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients
   Satoshi Hirase et al, 2016, Oncology Letters CrossRef
9. Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
   Zhiyang Wu et al, 2021, Cancers CrossRef
10. GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma
    Sharareh Gholamin et al, 2018, Journal of Cellular Physiology CrossRef
11. Circulating Tumor DNA in Pediatric Cancer
    Louise Doculara et al, 2022, Frontiers in Molecular Biosciences CrossRef
12. Bottom up proteomics identifies neuronal differentiation pathway networks activated by cathepsin inhibition treatment in neuroblastoma cells that are enhanced by concurrent 13-cis retinoic acid treatment
    Effie G. Halakos et al, 2021, Journal of Proteomics CrossRef
13. Dynamics of Minimal Residual Disease in Neuroblastoma Patients
    Suguru Uemura et al, 2019, Frontiers in Oncology CrossRef
14. The Application of and Factors Influencing, the NB5 Assay in Neuroblastomas
    Zuopeng Wang et al, 2021, Frontiers in Oncology CrossRef
15. Investigation of patient factors associated with the number of transfusions required during chemotherapy for high‐risk neuroblastoma
    Saori Konno et al, 2022, Vox Sanguinis CrossRef
16. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients
    NOBUYUKI YAMAMOTO et al, 2015, Oncology Letters CrossRef
17. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood
    Kyaw San Lin et al, 2021, Translational Oncology CrossRef
18. Polyphenols from marine brown algae target radiotherapy-coordinated EMT and stemness-maintenance in residual pancreatic cancer
    Sheeja Aravindan et al, 2015, Stem Cell Research & Therapy CrossRef
19. Opportunities and challenges of circulating biomarkers in neuroblastoma
    Ricky M. Trigg et al, 2019, Open Biology CrossRef
20. Kalirin-RAC controls nucleokinetic migration in ADRN-type neuroblastoma
    Elena A Afanasyeva et al, 2021, Life Science Alliance CrossRef
21. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients
    Khin K.M. Thwin et al, 2020, The Journal of Molecular Diagnostics CrossRef